Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation OROS methylphenidate study in methamphetamine use disorder
ACTRN12620000880943Phase 2Not yet recruiting
- Sponsor
- Christopher Gale
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylphenidate in methamphetamine use disorder (MUD), sponsored by Christopher Gale. Primary endpoint: Participant safety. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
methylphenidate
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on ACTRN12620000880943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000880943.